Pfizer to Buy King Pharmaceutical
By wchung | 03 Jul, 2026
Pfizer Inc., the world’s largest pharmaceutical company by revenue, said Tuesday it will buy pain drug maker King Pharmaceuticals Inc. for $3.6 billion in cash.
Pfizer is paying $14.25 per share for King. That’s a premium of 40 percent to the stock’s Monday closing price of $10.15. Pfizer gains products including the pain drug Avinza, and Embeda, an extended-release pain treatment that is designed to be abuse-resistant.
King, of Bristol, Tenn., has struggled in recent years as patents on several of its key drugs have expired or been thrown out.
The boards of both companies approved the deal. Pfizer said the purchase will add about 2 cents per share to its profit in 2011 and 2012, and 3 to 4 cents per share in each of the next three years.
In premarket trading, King shares soared to $14.12, up 39 percent from Monday’s close. Pfizer shares dipped 8 cents to $17.30.
NEW YORK (AP)
© 2026 by Asian Media Group Inc.
Recent Articles
- US-EU Trade Hits Record High Despite Tariff Tensions, Study Shows
- Chinese Independent Refiners Snap up Discounted Mideast Oil as Supplies Rise
- US Oil Companies See Big Profit Jump, Faces Pressure to Cut Pump Prices
- Drug Gangs Use Social Media to Recruit Thai Air Crew as Couriers
- Ghonhee Lee's Katalyst Launches Orbital Rescue Mission for NASA Satellite
- Zuckerberg Says Meta AI Agent Tech Progressing Slower Than Expected
- Japan's Services Activity Returned to Growth in June
- Air Force to Investigate Officer Who Called for Trump Impeachment
- How Americans Plan to Celebrate July 4th 250
- Tesla's China-Made EV Sales Jumped 24.4% on Year in June